| Field | Specification |
|---|---|
| Target | |
| Alternative names | NAT 05-239 |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C12H12N4OS |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Motapizone, also known as NAT 05-239, is a selective inhibitor of PDE3. It moderately inhibits cytokine release in lipopolysaccharide (LPS)-induced alveolar macrophages and inhibits human platelet aggregation by increasing intracellular cAMP[1][2]. It is supplied as a light yellow to yellow solid (C12H12N4OS, MW 260.31) at 95.0% purity.
Physical & Chemical Properties
| CAS Number | 90697-57-7 |
|---|---|
| Molecular Formula | C12H12N4OS |
| Molecular Weight | 260.31 g/mol |
| Purity | 95.0% |
| Appearance | Solid |
| Color | Light yellow to yellow |
| SMILES | CC(C1)C(C2=CC(N3C=CN=C3)=CS2)=NNC1=O |
| Target | PDE3 |
| Signaling Pathway | Metabolic Enzyme/Protease |
| Solubility | In Vitro: DMSO: 2.7 mg/mL (10.37 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 2.7 mg/mL (10.37 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
Data provided by the manufacturer.
In Vitro
Motapizone (10 μM; 15 min before oxidants) gives 20% inhibition of cytokine release in lipopolysaccharide (LPS)-induced alveolar macrophages under oxidative stress conditions, and this inhibitory effect is not influenced by oxidative stress[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
